TPM |
Transcripts per kilobase million |
ACC |
Adrenocortical carcinoma |
BRCA |
Breast invasive carcinoma |
CESC |
Cervical squamous cell carcinoma and endocervical adenocarcinoma |
COAD |
Colon adenocarcinoma |
DLBC |
Lymphoid neoplasm diffuse large B-cell lymphoma |
ESCA |
Esophageal carcinoma |
GBM |
Glioblastoma multiforme |
HNSC |
Head and neck squamous cell carcinoma |
LGG |
Brain lower grade glioma |
LIHC |
Liver hepatocellular carcinoma |
LUAD |
Lung adenocarcinoma |
LUSC |
Lung squamous cell carcinoma |
PAAD |
Pancreatic adenocarcinoma |
PRAD |
Prostate adenocarcinoma |
READ |
Rectum adenocarcinoma |
STAD |
Stomach adenocarcinoma |
THCA |
Thyroid carcinoma |
THYM |
Thymoma |
UCEC |
Uterine corpus endometrial carcinoma |
UCS |
Uterine carcinosarcoma |
EMT |
Epithelial-to-mesenchymal transition |
MAPK |
The mitogen-activated protein kinase |
JNK |
C-Jun N-terminal kinase |
ERK |
Extracellular signal-regulated kinase |
FGFBP1 |
Fibroblast growth factor-binding protein 1 |
SOX10 |
SRY-Box Transcription Factor 10 |
PI3K |
the phosphoinositide 3-kinase |
ERBB3 |
Erb-b2 receptor tyrosine kinase 3 |
VEGFA |
Vascular Endothelial Cell Growth Factor A |
TGF-β |
Transforming growth factor-β |
CCL2 |
C-C motif chemokine ligand 2 (monocyte chemoattractant protein-1,MCP-1) |
PD-L2 |
Programmed cell death 1 ligand 2 |
TDO2 |
Tryptophan 2,3-dioxygenase |
PRC2 |
Polycomb-repressive complex 2 |
E2F |
Transcription Factor |
ATM |
Ataxia telangiectasia-mutated gene |
DSB |
Double-strand breaks repair |
HR |
Homologous recombination |
NNHEJ |
Non-homologous DNA end joining |
AIs |
Aromatase inhibitors |
ER |
estrogen receptor |
DNMTs |
DNA methyltransferases |
G4 |
G-quadruplex |
CHD7 |
Chromodomain Helicase DNA Binding Protein 7 |
APC |
Anaphase-promoting complex |
BET |
Bromodomain and extraterminal domain |
MEK |
MAP kinase kinase |
PDX |
patient-derived tumor xenograft |